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1. Introduction 
Botulism is a neuroparalytic disease caused by neurotoxin produced from the bacterium 
Clostridium botulinum. The botulinum neurotoxins (BoNTs) are among the most potent 
known biological toxins and have an estimated human median lethal dose (LD50) in the 
nanogram/kilogram range. Botulinum toxins have historically been employed as biological 
weapons (BW) through state-sponsored programs in Japan, Germany, the United States, 
Russia and Iraq as well as by independent terrorist organizations. The extreme potency of 
the toxin, its persistence within affected neurons, the need for protracted intensive care, and 
the lack of an effective post-intoxication therapeutic intervention make BoNTs a potentially 
deadly offensive biological weapon.  
2. Botulinum neurotoxins as biological weapons 
2.1 Historical applications of botulinum toxins in biological warfare 
There have been reports of botulinum neurotoxin being used as an offensive weapon since 
the early 1900s. Anecdotal accounts describe the implementation of crude anaerobic 
fermenters made by burying canteens filled with water, green beans and slivers of meat to 
facilitate C. botulinum production for use against Mexican federal troops in 1910 (Carrus, 
2001). Documented state sponsored programs utilizing BoNT as a potential BW were 
reported as early as the 1930s when the military medical commander of Unit 731, General 
Shiro Ishii, confessed to feeding food contaminated with lethal cultures of C. botulinum to 
prisoners of war (Williams & Wallace, 1989). In the early 1940s, the US developed a BoNT-
based BW program in response to Allied intelligence reports that Germany was attempting 
to develop the neurotoxin as an offensive weapon to be used against an invasion force 
(Franz et al., 1997). The initial efforts of the US program were primarily directed at the 
isolation and purification of the toxin and the elucidation of the mechanism of pathogenicty 
of BoNT, then referred to as agent “X” (Cochrane, 1947). In response to the potential threat 
from Germany, over 1 million doses of a botulinum toxoid vaccine were prepared for Allied 
troops involved in the D-Day invasion in Normandy (Bryden, 1989). The 1972 Convention 
on the Prohibition of the Development, Production, and Stockpiling of Bacteriological 
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(Biological) and Toxin Weapons and on their Destruction signed by President Richard M. 
Nixon went into effect in March of 1975, effectively terminating the US BW efforts. All of the 
biological agent stockpiles created in the US offensive program, including botulinum 
neurotoxins, were destroyed. Despite being signatories on the convention, the Soviet Union 
continued not only to pursue its biowarfare program, including research on botulinum 
neurotoxins, but expanded their program during the post-Soviet era (UNSC, 1995; 
Bozheyeva et al., 1999). Botulinum toxins were reportedly one of several biological agents 
tested at the Soviet Aralsk-7 site on Vozrozhdeniye (Renaissance) Island in the Aral Sea. The 
Soviets were also believed to have attempted to use recombinant DNA technology to 
introduce BoNT genes into alternative strains of bacteria for the purpose of enhancing toxin 
production (Alibek & Handleman, 1999). Iraq, which also ratified the 1975 convention, 
reportedly also significantly expanded its biological weapons program (UNSC, 1995). After 
the Persian Gulf War, Iraq admitted to a United Nations Special Commission inspection 
team that approximately 4,900 gallons of concentrated botulinum neurotoxins had been 
produced for use in specially designed bombs, missiles and tank dispersion instruments in 
1989 (Zilinskas, 1997). Iraq maintains that no biological weapons were employed during the 
Persian Gulf War or Operation Iraqi Freedom and that its stockpiles have since been 
destroyed (Blix, 2004).  
The Japanese cult Aum Shrinkyo (now referred to as Aleph) attempted to develop both 
chemical and biological weapons after its political aspirations were defeated in the 1990 
Japanese Diet elections. Formed in 1987 by Shoko Asahara, this group developed rapidly 
and was reported to have 50,000 members and over US$ 1 billion in financial resources by 
1995 (Sugishima, 2003). The Aum executed a deadly sarin nerve gas attack in Matsumoto 
City on June 27, 1994 which killed seven people. On March 20, 1995 they perpetrated a sarin 
gas assault on a Tokyo subway which killed 12 people and injured over 1000 individuals. 
Less than a month later they attempted a cyanide gas release in a restroom of the subway’s 
Shinjuku Station. Senior Aum members obtained soil samples in an attempt to isolate toxin-
producing strains of C. botulinum. Despite the cult having members with a variety of 
scientific expertise, they are believed to have experienced difficulty cultivating toxigenic 
strains of C. botulinum and were most likely unable to produce any substantial amount of 
toxin (Sugishima, 2003; Leitenberg, 1999).  
2.2 Domestic threat targets 
The possibility of dissemination of toxins such as BoNT through municipal water supplies 
or centralized agricultural or food distribution hubs has been explored in a number of 
scenarios. There has never been a confirmed case of waterborne botulism. In 1980, 
Notermans & Havelaar reported on the stability of BoNT/A, /B and /E when introduced 
into samples of reservoir surface water, drinking water prepared by sand-filtration, and 
sterile distilled water. Toxicity was reduced 99% in just over 3 days in the surface water, 9 
days in filtered water and relatively stable in sterile distilled water. Treatment with FeCl3, 
a common coagulant processing step employed in municipal water treatments to remove 
iron, removed 75-95% of the toxins. Treatment with 1 mg of ozone per liter for 2 min 
destroyed ≥99% of the toxins and 0.3-0.5 mg/L sodium hypochlorite ablated 99% of the 
toxicity in 30 seconds. Despite the extreme potency of BoNTs, their application as a 
bioterrorism weapon by introduction into a water supply in the US would most likely be 
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unsuccessful when conventional municipal water treatment methods are employed 
(Notermans & Havelaar, 1980; Wannemacher, at al., 1993). Another consideration is that 
large-capacity reservoirs undergo a relatively slow turn-over rate and so a comparably 
large inoculum of botulinum toxin would be needed (Burrows et al., 1997). Given the 
technical difficulties involved in producing such a large amount of toxin, this route seems 
unlikely. Small-scale (personal-use) water filtration systems utilizing ceramic or 
membrane filters with a 0.2 to 0.4 m pore size were found to be insufficient to effectively 
remove BoNT/B introduced into drinking water. However, a reverse osmosis device was 
found to remove BoNT levels below the detection limit of the mouse bioassay (Hörman, et 
al. 2005).  
American agriculture has been described as being “concentrated, highly accessible, 
vertically integrated” and as such, susceptible to the malicious introduction of biological 
toxins or human pathogens at processing or distribution points that would reach consumers 
before a significant threat was realized (Parker, 2002). Wein and Liu published a 
mathematical model to predict the effects of the deliberate introduction of botulinum toxin 
at various points through the nine-stage milk collection, processing and distribution 
network in the US, as it is associated with a single processing facility (Wein and Liu 2005). 
The study has a number of variables such as the amount of toxin employed, the total 
volume of the milk, the specific effect of the pasteurization process on the toxin and variable 
delivery time and consumptions rates, but all scenarios support a significant outbreak of up 
to 100,000 individuals. The report generated considerable controversy but the editors of the 
publishing journal defended the release, citing its potential contribution to developing 
defensive counter-measures as well as informing federal and state governments of the 
putative threat (Alberts, 2005). The devastating potential of an intentional bioterrorism 
attack using this avenue was illustrated in 1985 when almost 200,000 people were infected 
with an antibiotic-resistant strain of Salmonella caused by an inadvertent contamination at a 
single northern Illinois dairy processing plant (Ryan, et al., 1987).  
The potential susceptibility of centralized food distribution platforms in the US can be 
illustrated by outbreaks attributed to improper processing of mass distributed 
consumable products. In September 2006, a total of 6 individuals from 2 US states and 1 
Canadian province were admitted to local hospitals with cranial neuropathies and 
flaccid paralysis necessitating mechanical ventilation (CDC, 2007). All of the individuals 
tested positive for BoNT/A and one patient eventually died. The outbreaks were traced 
to a commercially produced carrot juice manufactured in a single plant which was 
distributed under three different brand labels. The intoxications were attributed to a 
lapse in refrigeration during transport or storage and a lack of chemical barriers to C. 
botulinum germination during processing. In the summer of 2007, 8 cases of botulism in 3 
US states led to a massive recall of canned meat products. The outbreaks were traced to 
product from a single production line in a single plant that was packaged and 
distributed under 90 different labels (NCFPD, 2008) and which necessitated the recall of 
tens of millions of cans of suspect food. While these outbreaks represent unintentional 
distribution of BoNT, they do reveal the complexity of the food production and 
distribution network in the US and how it might be compromised by a BW attack using a 
potent toxin such as BoNT. 
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3. Microbiology and BoNT toxicity 
3.1 The organism and its toxins 
Clostridium spp. are gram-positive, spore-forming, obligate anaerobic bacteria that are 
ubiquitous in soil and both freshwater and marine sediment (Dunbar, 1990) . BoNTs are 
produced primarily in C. botulinum but may also be produced in the closely related C. 
butyricum, C. baratii and C. argentinense (Hatheway, 1993). C. botulinum strains are 
classified into four groups (denoted I to IV) based on metabolic activity (Hatheway, 1988) 
and genetic composition (Collins, 1998; Hill et al., 2007). Group I includes type A strains 
and proteolytic strains of types B and F; Group II includes type E strains and 
nonproteolytic strains of types B and F; Group III includes nonproteolytic strains of types 
C and D; and Group IV includes only strains that produce type G. There are seven 
immunologically distinct serotypes of BoNTs designated by the letters A through G 
(BoNT/A to BoNT/G) (Smith & Sugiyama, 1988). BoNT/A, based on animal studies, has 
a lethal human dose (LD50), assuming 70 kg weight, of approximately 0.09 - 0.15 g by 
intravenous administration, 0.7 – 0.9 g by inhalation, and 70 g by oral administration 
(Scott & Suzuki, 1988; Arnon et al., 2001). The toxicity for other serotypes is unknown but 
all have been shown to uniformly fatal in animals studies. Human botulism is caused 
primarily by BoNT/A, /B and /E (Arnon et al., 2001), and rarely by BoNT/F (Barash et 
al., 2005; Gupta et al., 2005). BoNT/C and /D primarily cause botulism in animals. 
BoNT/G, produced by C. argentinense, has been associated with sudden death but not 
neuroparalytic illness in a few patients in Switzerland (Sonnabend et al., 1981). All seven 
serotypes can cause inhalational botulism in primates (Middlebrook & Franz, 1997). 
Recent characterization of an increasing number of unique BoNT subtypes has revealed 
small to significant variations at the amino acid level (Smith, et al., 2005; Hill, et al. 2007; 
Smith, et al., 2007). These variations impact binding and protection of neutralizing 
antibodies (Smith, et al., 2005) and raise concerns that they may prove problematic to the 
development of prophylactic and therapeutic agents developed against a dissimilar 
subtype. 
BoNTs are produced as a part of a protein complex in which the toxin is non-covalently 
bound to two or more protein components. This includes the well characterized 
hemagglutinins (HA) and a nontoxin, nonhemagglutinin (NTNH). The complexes can be 
distinguished on the basis of their size and serotype association and include the M-(300 kDa 
in types A-F), L-(500 kDa in serotypes A, B, C, D and G) and LL-(900 kDa in serotype A) 
forms (Collins & East, 1988). Although neither accessory protein has been implicated in the 
toxin-mediated blockade of neurotransmitter release, they are believed to protect the toxin 
against the harsh environment of the gastro-intestinal tract (Simpson, 2004). The neurotoxin 
is initially produced as a 150-kDa single-chain protoxin that is proteolytically cleaved into 
an N-terminal 50-kDa light chain (LC) and a C-terminal 100-kDa heavy chain (HC) di-chain 
that is linked by a single disulfide bond (DasGupta, 1989). The BoNT HC is further 
delineated into two domains; the N-fragment or translocation domain (Hn) and the C-
fragment or receptor-binding domain (Hc). These three domains mediate intoxication of the 
neuron in a defined tripartite mechanism. The toxin is introduced into the nerve cell by 
receptor-mediated endocytosis through binding of the Hc domain to specific ectoreceptors 
on peripheral cholinergic nerve cells (Dong et al., 2006; Rummel et al., 2007). The acidic pH 
of the endosome initiates a conformation change in the dichain toxin that results in the Hn 
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forming a protein channel that facilitates the translocation of the LC out of the endosomal 
lumen and into the cytosol. The LC is a zinc-containing endopeptidase that target SNARE 
(soluble N-ethylmaleamide sensitive factor attachment protein receptors) proteins that form 
the synaptonemal fusion complex in a serotype dependent fashion. The SNARE protein 
SNAP-25 (synaptosomal-associated protein of 25 kDa) is cleaved at different sites by 
BoNT/A, /C, and /E, synaptobrevin (also referred to as VAMP; vesicle-associated 
membrane protein), is cleaved at different sites by BoNT/B, /D, /F, and /G, and syntaxin is 
cleaved by BoNT/C (Simpson, 2004). Proteolytic cleavage of SNARE proteins prevents the 
release of acetylcholine across the synaptic cleft of the neuromuscular junction, resulting in a 
flaccid muscle paralysis which is the primary clinical sign of botulism. 
3.2 Epidemiology 
Botulism is typically reported in four clinical categories. Foodborne botulism is caused by the 
ingestion of the pre-formed toxin in contaminated food (CDC, 1998). Most outbreaks are 
associated with home-canned foods in which inadequate processing results in C. botulinum 
spores germinating, reproducing and producing the toxin (Shapiro, et al., 1998). These 
conditions include an anaerobic environment with temperatures ranging from 4ºC to 40°C, a 
pH range from 4.6 to 7.0, and water activity greater than 0.94 (aW is intensity with which 
water associates with various non-aqueous constituents and solids) (Baird-Parker & Freame, 
1967; Stringer, et al., 2005). Despite increased educational awareness of the non-permissive 
conditions for food preparation, foodborne botulism remains a persistent threat. There were, 
on average, approximately 24 reported cases per year from 1900-2000, but there have been a 
smaller number of cases (average of 18 year) reported from 2001-2009 (CDC-NBS). In the 
period from 1950-1996, there were 444 outbreaks in which one or more cases of botulism 
from a contaminated food source was implicated. Of these outbreaks, 37.6% were caused by 
type A, 13.7% by type B, 15.1% by type E and 0.7% by type F while 32.9% of the incidents 
were caused by unidentified serotype(s) (CDC, 1998). Improvements in both differential 
diagnostic methods and the technology utilized in serotyping have resulted in a decrease in 
unidentified serotypes. In the United Stated from 1990-2000 BoNT/A was responsible for 
50% of all cases of botulism, where types B and E were responsible for 10% and 37% of the 
intoxications, respectively; only 3.6% of the cases were from an unidentified strain (CDC, 
1998).  
Infant botulism is a toxicoinfection caused by inhalation or ingestion of clostridial spores that 
can colonize and produce toxin in the intestinal tract of infants less than 12 months of age 
(Shapiro, 1998). The ability of the bacteria to thrive and elicit toxin is thought to be 
attributed in part to a deficiency in protective gastrointesintal bacterial flora and the 
relatively low levels of inhibitory bile-aid found in children under 12 months (CDC, 1998). 
This form of the disease was officially recognized in a 1976 report in which two infants 
presenting with acute infantile hypotonoia and weakness were diagnosed with botulism 
(Pickett, et al., 1976). This has been the most commonly reported form of the disease in the 
United States since 1980, with an average of approximately 80-100 cases confirmed annually 
(Shapiro, 1998). In the US between 1976 and 1996, there were 1442 individual cases of infant 
botulism reported to the CDC (CDC, 1998). Of these, 46.5% were caused by type A, 51.9% by 
type B. Interestingly, the incidence of infant botulism in the US has a geographical 
component with 47.6% of the reported cases occurring in California with Delaware, Hawaii, 
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and Utah also experiencing high incidence (CDC, 1988). The correlation between the 
increased incidences of infant botulism outbreaks associated with certain geographical 
locations has not been elucidated.  
Wound botulism (WB) results from the growth of C. botulinum spores in a contaminated 
wound with in vivo toxin production. This form of the disease was first reported in 1951 as 
a relatively rare illness associated with post-operative complications (Davis et al., 1951). 
Historically, approximately 75% of the wound botulism cases in the US have been reported 
in California (Weber, et al., 1993) and this represents over 90% of the reported incidences in 
the world (Benson, 2001). There were 127 cases of wound botulism in California from 1951 
to 1998. Of these, 105 were attributed to intravenous drug users and all but one were 
admitted black-tar heroin users (Benson, 2001). The increased incidence of WB in California 
has not abated and between 1993 and 2006 an additional 17 cases were identified in 
intravenous drug users; 16 of which were diagnosed with one or more recurrent episodes 
(Yuan et al., 2011).  
Adult intestinal toxemia botulism is a rare toxicoinfection that occurs in older children and 
adults with abnormal gastrointestinal tract physiology, such as colitis or intestinal surgical 
procedures (Freeman et al., 1986; Fenecia et al., 1999). The disease has also been correlated 
with alteration of protective endogenous microflora by broad-spectrum antibiotics after 
inflammatory intestinal disease or surgery (Chia et al., 1986). 
In addition to the four naturally occurring forms of the disease described previously, there 
are two additional forms of inadvertent botulism that result from the application of the 
purified toxin. Iatrogenic botulism results from the injection of BoNT for either cosmetic or 
therapeutic purposes. Two adult patients developed symptoms of botulism when given 
therapeutic doses of BoNT/A drawn from two different production lots (Bakheit, 1997). 
These cases have since been attributed to either patient sensitivity to the drug or the 
inadvertent injection of the toxin directly into the vascular capillaries. An adolescent being 
treated for spastic quadriparesis with Myobloc (botulinum toxin serotype B) developed 
clinical signs of a systemic BoNT injection (Partikian, 2007). While there are no clear dosing 
guidelines for BoNT formulations for therapeutic interventions in children, the clinical 
diagnosis of botulism was again believed to have been the result of inadvertent injection 
into a blood vessel or diffusion from nearby muscle sites. In November of 2007, four adults 
were given cosmetic injections of undiluted BoNT/A intended for laboratory research 
(Chertow et al., 2006). Serial dilutions of two of the individual’s serum samples indicated 
they were given approximately 21 to 43 estimated human lethal doses. All four patients 
survived but only after prolonged hospitalization with anti-toxin treatment and ventilator 
support ranging from 40 to 104 days.  
Inhalational botulism is intoxication by an inhalational exposure of the aerosolized toxin. The 
only reported human inhalation incidence occurred in Germany in 1962 during a necropsy 
when three laboratory workers were exposed to animals subjected to aerosolization of a 
highly purified, lyophilized BoNT/A (Holzer, 1962). The patients were hospitalized five 
days postexposure, administered equine antitoxin, and discharged after 9 days. While not a 
naturally occurring form of the disease, inhalational botulism has implications as a potential 
weapon of bioterrorism (Middlebrook & Franz 1997; Zilinskas, 1997). An aerosol dispersion 
of BoNT could create a toxic gas cloud that could encompass a large area and is considered 
to be a likely scenario for a terrorism attack.  
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3.3 Clinical symptoms 
The clinical presentation of botulism is characterized by distinctive neurological symptoms 
of the voluntary motor and autonomic cholinergic-associated junctions in the infant, wound 
and intestinal forms of the disease (CDC, 1998). Foodborne botulism is often accompanied 
by acute gastrointestinal distress including nausea, abdominal cramps, vomiting and 
diarrhea that precede the neurological symptoms (Hughes et al, 1981), particularly in types 
B and E. The initial symptoms of food botulism can manifest anywhere from within a few 
hours to several days postintoxication. The time to onset of symptoms, the severity and the 
duration of the disease is largely dictated by the exposure dose and the serotype (Arnon, 
2001; Woodruff et al., 1992). Infant botulism may present with constipation, poor feeding, 
diminished suckling, neck and peripheral weakness, weak crying increased drooling 
(Corblath, et al., 1993) and ventilatory failure (Arnon, 1992; Long et al., 1985). Wound 
botulism does not display the gastrointestinal symptoms observed in the foodborne form. 
Fever, if present, is generally attributed to a wound infection rather than botulism.  
The neuroparalytic effects of botulism present as an acute, afebrile, descending, bilateral 
flaccid paralysis. The initial neurological symptoms generally involve cranial nerves III, IV 
and VI (Sobel, 2005) and include ocular disorders such as blurred vision, diplopia, ptosis 
and photophobia (Terranova et al., 1979). This is generally followed by dysfunction of 
cranial nerves VII and IX which cause, dysphagia, dysphonia and dysarthia. The 
neurological impairment may then spread to the upper extremities, the trunk and then the 
lower extremities. Respiratory distress can be caused by a weakened glottis that tends to 
obstruct the airway during attempted inspiration or from paralytic weakness of the 
diaphragm and parasternal and intercostas muscles. Fatigue, sore throat, dry mouth, 
constipation and dizziness have also been reported to be associated with botulinum 
intoxications (Hughes, 1981). Fatalities are most often the result of respiratory failure or 
secondary infections typically associated with prolonged mechanical ventilation. Bleck 
summarized the clinical findings of several published reports of foodborne botulism by 
symptom and serotype as shown in Table 1 (Bleck, 2000).  
The primary neurological disorders associated with botulism are common to the foodborne, 
intestinal, and wound forms of the disease (Sobel, 2005). The duration and severity of the 
neuroparalytic effects of the disease can be influenced by both the amount and serotype of 
the toxin introduced into the system. Insight into the impact of the different serotypes in 
humans has only recently been investigated and much of the data comes from studies 
involving the therapeutic applications of BoNTs. Of the three most prevalent serotypes 
involved in human incidences of botulism, BoNT/A has been shown to have the most 
persistent action and can last 12-16 weeks when used in therapeutic applications (Eleopra, 
2004). Serotype B has also been used in therapeutic applications but only exhibits the 
comparable efficacy to BoNT/A when used in higher doses (Sloop, et al., 1997; Settler, 2001). 
Electrophysiological studies conducted in juvenile monkeys using purified BoNT/A 
(BOTOX, Allergan, Irvine, CA) and BoNT/B (Neurobloc, Elan, Shannon, Ireland) indicated 
BoNT/A diffusion was more pronounced (Arezzo, 2001). The few studies pertaining to 
serotype C in humans (Eleopra et al., 1997; Eleopra et al., 1998a, Eleopra et al., 1998b) 
indicate that it is similar to BoNT/A in terms of the toxicity and duration of activity. A 2004 
study evaluated the electrophysical responses to human volunteers injected with low doses 
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      Type A (%)   Type B (%)   Type E (%) 
 
Neurological symptoms 
Dysphagia    96   97   82 
Dry mouth    83  100   93 
Diplopia    90   92   39 
Dysarthia    100   69   50 
Upper extremity weakness  86   64  NA 
Lower extremity weakness  76   64  NA 
Blurred vision    100   42   91 
Dyspnea    91   34   88 
Paresthesiae    20   12  NA 
Gastrointestinal Symptoms 
Constipation    73   73   52 
Nausea     73   57   84 
Vomiting    70   50   96 
Abdominal cramps   33   46  NA 
Diarrhea    35   8   39 
Miscellaneous symptoms 
Fatigue     92   69   84 
Sore throat    75   39   38 
Dizziness    86   30   63 
Neurological Findings 
Ptosis     96   55   46 
Diminished gag reflex   81   54  NA 
Ophthalmoparesis   87   46  NA 
Facial paresis    84   48  NA 
Tongue weakness   21   31   66 
Pupils fixed or dilated   33   56   75 
Nystagmus    44   4  NA 
 
Upper extremity weakness  91   62  NA 
Lower extremity weakness  82   59  NA 
Ataxia     24   13  NA 
DTRs diminished or absent  54   29  NA 
DTRs hyperactive   12   0  NA 
Initial mental status 
Alert     88   93   27 
Lethargic     4   4   73 
Obtunded     8   4   0 
 
DTRs, deep tendon reflexes; NA, not available. 
Table 1. Summary of Symptoms of Patients with Botulism Caused by Serotypes A, B an E. 
from Springer Scientific Publishing. 
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of BoNT/A, /B, /C or /F (Eleopra et al., 2004). The results were consistent with other 
research efforts in that BoNT/B, used in higher doses, and BoNT/C have a similar profile as 
BoNT/A. As reported in previous studies (Mezaki et al., 1995; Chen et al., 1998), BoNT/F 
was found to have a shorter duration compared to BoNT/A.  
3.4 Diagnosis of botulism 
A rapid and accurate identification of botulism is not difficult when the disease is strongly 
suspected, such as found in the setting of a large outbreak. But because cases of naturally 
occurring botulism most often occur singularly, the individual diagnosis may prove more 
challenging. Botulism is thought to be substantially underdiagnosed (CDC, 1988) and with 
low-level exposure, minor neurological manifestations of the disease may resolve without 
medical intervention. A differential diagnosis of botulism without concurrent knowledge of 
a confirmed outbreak can be difficult and other paralytic illnesses may need to be excluded. 
These include Guillain-Barre syndrome, myasthenia gravis, tick paralysis, and Eaton-
Lambert syndrome (Dembek, et al., 2007). Less likely conditions such as tetrodotoxin and 
shellfish poisoning, aminoglycoside toxicity and a variety of other neurotoxic products and 
neurological abnormalities may initially present with similar symptoms. However, a 
thorough medical examination of the patient and their medical history can generally 
exclude any competing diagnosis. A patient presenting with an acute, bilateral, descending 
flaccid paralysis that is afebrile and has normal sensorium should suggest a clinical case of 
botulism. 
The most reliable method for the detection of BoNTs and for diagnosing botulism is the 
mouse bioassay. This test can be performed by the Centers for Disease Control and 
Prevention (CDC) or state public health laboratories. The assay involves injecting mice with 
samples collected from patients displaying symptoms of botulism. Mice will typically begin 
showing signs of botulism within 8 h. The serotype of samples can also be ascertained in this 
manner by neutralizing the toxin with serotype-specific antibodies prior to injecting the 
mice (Shapiro et al., 1998). In cases of foodborne or infant botulism, stool samples can also 
be cultured to look for C. botulinum. Samples of the suspected food should also be cultured 
anaerobically with heat or alcohol treatment to select for spores.  
4. Medical countermeasures 
4.1 Current medical intervention 
Standard therapy for botulism involves administration of botulinum antitoxin in an 
attempt to prevent neurologic progression of a moderately progressive illness, or to 
reduce the duration of respiratory failure in individuals with a severe, rapidly progressive 
illness. This is done in conjuction with careful monitoring of respiratory vital capacity and 
aggressive ventilatory care for individuals that display respiratory failure. The only 
specific pharmacological treatment for botulism is administration of equine-derived 
botulinum antitoxin. On March 12, 2010, a new heptavalent botulinum antitoxin (HBAT, 
Cangene Corp.) became available through a US CDC-sponsored FDA Investigational New 
Drug (IND) protocol for the treatment of naturally acquired non-infant botulism (CDC, 
2010). This antitoxin replaced the previously FDA-approved equine bivalent botulinum 
antitoxin AB and an investigational monovalent equine antitoxin E (BAT-AB and BAT-E, 
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Sanofi Pasteur). HBAT contains equine-derived antibody against all BoNT serotypes: 
7,500 U anti-A; 5,500 U anti-B; 5,000 U anti-C; 1,000 U anti-D; 8,500 U anti-E; 5,000 U anti-
F; and 1,000 U anti-G per vial. This antitoxin is composed of <2% intact immunoglobulin 
G (IgG) and ≥90% Fab and F(ab’)2 immunoglobulin fragments created by despeciation 
(CDC, 2010). The recommended adult dosing is one 20 mL vial of HBAT (McLaughlin and 
Funk, 2010). BabyBIG®, human botulism immune globulin intravenous (BIG-IV), is an 
FDA-approved drug for the treatment of infant botulism types A and B. Available 
through the California Infant Botulism Treatment and Prevention Program, BabyBIG® is 
obtained from the pooled plasma of adults vaccinated with the pentavalent (A-E) 
botulinum toxoid who displayed high titers of neutralizing antibodies against BoNT/A 
and /B. Because BabyBIG® is of human origin, it does not carry the risk for anaphylaxis 
inherent with equine products, nor does BabyBIG® demonstrate a risk for possible 
lifelong hypersensitivity to equine antigens. BabyBIG® has been shown to significantly 
shorten the hospitalization period and reduce treatment costs up to $75,000.00 per 
incident (Thompson et al., 2005; Fox, 2005).  
Antitoxin can neutralize toxin molecules that are not yet bound to nerve endings and may 
limit the progression of the disease and prevent further nerve damage by clearing them 
from circulation. Thus, the antitoxin should be administered immediately upon a 
definitive diagnosis of botulism, preferably within 24 h after the onset of symptoms 
(Tacket et al., 1984; Chang and Ganguly, 2003). Compared to standard care alone, 
immediate administration of antitoxin has been shown to shorten time on respiratory 
support, and also reduced the hospitalization period (Shapiro et al., 1997; Tacket et al., 
1984). It is not clear how long the toxin can persist in the bloodstream before clearance. 
Ravichandran reported that BoNT/A had a serum half-life of approximately 4 hours in 
small animal studies (Ravichandran et al., 2005). This study also suggested that blood 
does not sequester or modify the toxin in any detectable way. Thus, the blood may act as a 
reservoir for the toxin until it either enters the target cells or is eliminated from the body. 
Detectable levels of toxin were observed in one of the four patients in the Florida outbreak 
8 days after receiving a massive overdose of an unlicensed preparation of BoNT/A during 
a cosmetic procedure (Chertow et al., 2006). Under such circumstances, antitoxin 
administration, even if delayed, may still be effective in limiting the duration of the 
illness. The use of equine-based antitoxins, but not the human product, has been 
associated with symptoms of hypersensitivity (including urticaria, serum sickness, and 
anaphylaxis). Hence, dermal testing is required before antitoxin administration. Due to 
the risk of adverse reactions, prophylactic antitoxin is not recommended in patients who 
are exposed to BoNT but have no symptoms. These patients may undergo gastric lavage 
or induced vomiting in an attempt to eliminate the toxin before absorption (Chan-Tack & 
Bartlett, 2010). 
4.2 Prophylaxis  
In the United States, there is currently no FDA-licensed prophylactic product against 
botulism. Some of the earliest vaccine efforts were initiated during the second World War 
due to concerns that the toxin might be employed as an offensive biological weapon against 
the allied forces by Germany. A bivalent A/B toxoid vaccine was produced from 3-day 
culture autolysates of C. botulinum that were chemically neutralized with formaldehyde, 
filtered and adsorbed onto an alum adjuvant. While the vaccine did elicit the production of 
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neutralizing antibodies, it also displayed a number of localized and systemic reactogenic 
effects (Reames et al., 1947). An improved product in which the A and B toxins were 
purified to 10-15% homomgeneity by acid-precipitation of the culture supernatants and 
adjuvanted onto aluminum phosphate was found to be well-tolerated in humans, displayed 
only minor localized reactogenic effects and produced significantly improved antibody 
titers over the previous bivalent toxoid (Fiock et al., 1961). A pentavalent ABCDE toxoid 
vaccine with 1% thymerosol as a preservative prepared by Parke, Davis and Company was 
administered to approximately 400 individuals (Fiock et al., 1963). The vaccine displayed 
minor reactogenic effects and elicted detectable antibody titers to all five serotypes. This 
product was administered to over 1600 individuals from 1970 to 1981 under an 
Investigational New Drug (IND) application. The Michigan Department of Public Health 
produced a pentavalent botulism (ABCDE) toxoid (PBT) using similar procedures as the 
Parke Davis product, but which contained roughly 50% of the formaldehyde and only 0.01% 
thymerosol, that has been administered under an IND to at-risk laboratory workers and 
military personnel. However, the declining immunogenicity, dwindling supplies and local 
reactogenic effects of the PBT (Rusnak & Smith, 2009; CDC, 2009) have led to recent efforts 
to create new vaccines.  
More contemporary toxoid vaccines have been created by chemical neutralization of the 
purified toxin (Keller, 2008; Jones, et al., 2008). However, large scale production of these 
products would require a secure, CDC-licensed facility to both propagate large amounts the 
bacterium and manipulate the purified toxin. Subsequent efforts have largely relied on the 
expression of recombinant protein antigens encoding one or more of the BoNT domains.  
Codon optimized genes encoding the BoNT (Hc) antigens produced in a P. pastoris 
expression platform have been successfully developed as a recombinant subunit vaccine 
against serotypes A-F and have been demonstrated to elicit protective immunity in both 
rodent (Smith, 2009; Rusnak & Smith 2009) and non-human primates (Boles et al., 2006; 
Morefield, 2008). In February of 2011, the Dynport Vaccine Company announced that phase 
II clinical trials of a recombinant bivalent Hc vaccine against serotypes A and B (rBV A/B) 
had been completed and that full licensure would be sought. (CSC, 2011). Recombinant, 
catalytically inactive BoNT holoproteins made by mutagenesis of key amino acids residues 
have also been employed as potential vaccine candidates. A recombinant BoNT/C protein 
with active site mutations H229G, E230T and H223N produced in E. coli displayed no catalytic 
activity and elicited protective immunity against the parental toxin when delivered either 
subcutaneously or orally (Kiyatkin et al., 1997). Pier described the expression of a 
recombinant BoNT/A gene bearing R363A and Y365F mutations in the LNT01 nontoxigenic 
strain of C. botulinum (Pier et al., 2008). The recombinant protein was unable to cleave 
SNAP-25 and elicited protective immunity in mice when challenged with BoNT/A. 
Recombinant BoNT/A with active site mutations H223A, E224A and H227A produced in  
P. pastoris was found to be completely non-toxic and provided protective immunity in mice 
against 1000 MLD50 of not only the parental toxin, but against subtypes /A2 and /A3 as 
well (Webb et al., 2009).  
4.3 Post-intoxication interventions 
Once the neurotoxic LC is endocytosed within the cytosol of peripheral cholinergic 
neurons, circulatory antibodies will no longer be effective at neutralizing the catalytic 
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activity and ablating the toxicity. A number of recent research efforts have focused on the 
development of small-molecule inhibitors to reduce or eliminate the cleavage of SNARE 
proteins in neurons. The drawbacks associated with the use of peptides as drug 
candidates (e.g., poor tissue penetration, serum resistance, oral bioavailability, and quick 
elimination), and the potential usefulness of small molecules as pre- and post-exposure 
therapeutic agents have led many laboratories to instead pursue small-molecule 
approaches. To date, research has focused predominantly on developing small-molecule 
inhibitors that target the BoNT/A LC protease, due to the serotype’s persistence and 
highly toxic nature. A number of BoNT/A small-molecule inhibitors, identified using 
conventional and novel approaches, have been reported that exhibit varying degrees of 
inhibitory capacity (Burnett et al., 2003; 2009; Boldt et al., 2006; Park et al., 2006; Tang et 
al., 2007; Capkova et al., 2007; 2009; Moe et al., 2009; Roxas-Duncan et al., 2009; Burnett et 
al., 2010). Most of these studies were conducted in vitro using truncated forms of the LC 
which might not be structurally representative of the intracellular form of BoNT. The 
inhibitors reported by Roxas-Duncan et al (2009), identified via a hierarchical screening 
strategy, were evaluated in vitro using both forms of LC (truncated and full-length), and 
ex vivo using mouse phrenic nerve hemidiaphragm preparations. Despite intensive 
efforts on small-molecule inhibitor discovery and development, no compound has been 
identified that would be suitable for preclinical testing. At present, there are only two 
reports of BoNT/A small-molecule inhibitors that have been tested in vivo. Janda and co-
workers described a mouse toxicity bioassay in which two different inhibitors were 
injected intravenously immediately after an injection of 5-10 i.p. LD50 of BoNT/A. One 
compound, given at a 2.5 mM dose, showed a 36% increase in time to death, while the 
other, given at a 1 mM dose, resulted in a 16% overall survival rate (Eubanks et al., 2007). 
In another study, a single dose of three different inhibitors was administered i.p. at 2 
mg/kg 30 min prior to a challenge of 5 MLD50 of BoNT/A (Pang et al., 2010). The control 
mice died within 12 hrs. All 3 inhibitors provided 100% protection at 12 hrs and one 
compound provided 70% and 60% survival rates at 24 and 48 hrs; all three inhibitors 
provided a 10% overall survival rate with no signs of botulism at 5 days.  
Recently, other regions of the LC, in addition to the BoNT active site, generated attention as 
potential targets for inhibition. Merrino et al., (2006) has focused on a family of bis-
imidazole BoNT/A inhibitors targeting the peripheral sites of substrate binding. Silhar et al., 
(2010) reported on D-chicoric acid, a natural product isolated from Echinacea, that inhibits 
BoNT/A LC by binding to an exosite. 
4.4 Human recombinant monoclonal antibodies 
Currently, immunotherapy is deemed as the most effective immediate response to BoNT 
exposure. However, BabyBig® is exclusively approved for use in infants, and equine 
antisera can induce serum sickness and anaphylaxis (Arnon et al., 2001; Arnon, 2004). 
Monoclonal antibody (mAb) combinations (oligoclonal antibodies) may be viable substitutes 
for polyclonal antisera (Nowakowski et al., 2002; Razai et al., 2005). Construction of scFv 
phage Ab libraries has enabled the generation of large panels of high-affinity binding 
monoclonal antibodies. Mouse neutralization studies revealed that effective protection is 
observed only when combinations of three or more mAbs are used (Nowakowski et al., 
2002; Marks, 2004). Under the aegis of the National Institute of Allergy and Infectious 
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Diseases (NIAID), antibody combinations that effectively protect against multiple BoNT/A, 
/B, and /E subtypes are currently being produced and tested to support FDA licensure. 
Antibodies that protect against the four remaining toxin serotypes (BoNT/C, /D, /F, and 
/G) are also in development.  
4.5 Antibodies specific for the catalytic light chain 
While a majority of the BoNT immunotherapy research has been focused on antibodies that 
bind the HC, efforts were also directed to explore the potential for antibodies that bind the 
enzymatic LC. Using a novel hybridoma method for cloning human antibodies (Adekar et 
al., 2008; Dessain et al., 2004), a fully human antibody specific for the BoNT/A LC was 
isolated which potently inhibited BoNT/A in vitro and in vivo, via mechanisms not 
previously associated with BoNT-neutralizing antibodies (Adekar et al., 2008). In another 
study, Dong et al. (2010) created a library of non-immune llama single-domain VHH 
(camelid heavy-chain variable regions) displayed on the surface of the yeast Saccharomyces 
cerevisiae. Library selections against BoNT/A LC yielded 15 yeast-displayed VHHs, eight of 
which inhibited the cleavage of substrate SNAP-25 by BoNT/A LC. The most potent VHH 
(Aa1) had a solution K(d) of 1.47 x 10-10 M and an IC50 of 4.7 x 10-10 M. X-ray crystal structure 
of the BoNT/A LC-Aa1 VHH complex revealed that the Aa1 VHH binds the alpha-exosite 
region of BoNT/A LC. Recently, Tremblay et al. (2010) reported on the selection of small (14 
kDa) binding domains specific for the protease of BoNT serotypes A or B from libraries of 
VHHs or nanobodies cloned from vaccinated alpacas. Several VHHs were demonstrated to 
exhibit high affinity (KD near 1 nm) and were potent inhibitors of BoNT/A LC (Ki near 1 
nM); a VHH inhibitor of BoNT/A LC was able to protect BoNT/A-mediated SNAP25 
cleavage. 
4.6 Inhibitors of internalization and translocation  
Several compounds that inhibit the acidification process of endosomes by various 
mechanisms have been evaluated for both toxicity and ability to inhibit BoNT-induced 
synaptic failure. Lysosomotropic agents ammonium chloride and methylamine 
hydrochloride have been shown to antagonize the toxin internalization step by delaying the 
time-to-block of nerve-evoked muscle contractions after exposure to BoNT/A, /B, /C1, and 
TeNT (Simpson, 1983). However, these amines act by inhibiting the acidification process of 
endosomes; they do not selectively inactivate the toxins nor irreversibly modify tissue 
function at concentrations that inhibit the onset of BoNT-induced paralysis. Other 
candidates that have been examined were uncouplers of oxidative phosphorylation CCCP, 
FCCP (Adler et al., 1994), and vesicle H+-ATPase inhibitors including Bafilomycin A, which 
was shown to antagonize BoNTs A-G (Simpson et al., 1994). Some of these compounds were 
toxic or had low safety margins, hence they were deemed unsuitable as therapeutic 
candidates.  
Anti-malarial compounds chloroquine and hydroxychloroquine have also been evaluated 
for potentially inhibiting BoNT-mediated internalization (Simpson, 1982). The efficacy of 
these agents was found similar to that of ammonium chloride and methylamine 
hydrochloride; both groups also exhibited a comparable therapeutic window. Deshpande 
and co-workers (1997) extended the studies on antimalarial agents by examining a large 
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group of 4- and 8-aminoquinolines. Unfortunately, these compounds failed to extend the 
therapeutic window. The most effective compounds were 4-aminoquinolines and quinacrine 
that delayed BoNT/A-induced neuromuscular block by more than threefold compared to 
the control (toxin only) values. Maximum protection was solely achieved when the tissues 
were exposed to the compounds before or at the same time as the toxin treatment; a delay of 
>20 min abolished the inhibitory capacity of these compounds.  
An additional approach to prevent or reduce BoNT internalization has been attempted by 
treating nerve-muscle preparations with the protein ionophores nigericin and monensin 
(Adler et al., 1994; Sheridan, 1996). These ionophores block vesicle acidification by acting as 
H+ shunts to neutralize pH gradients, thereby interfering with the delivery of active LC in 
the cytosol. Though the efficacy of these ionophores was observed to be comparable to other 
inhibitors of internalization, they were more toxic; high concentrations resulted in a 
depression of neuromuscular transmission (Adler et al., 1994; Sheridan, 1996).  
4.7 Compounds that restore neuronal function 
A known potassium channel blocker, 3,4-diaminopyridine (3,4-DAP) was evaluated for its 
ability to antagonize BoNT-induced depression of tension in rat diaphragm muscles (Adler 
et al., 1995). BoNT-induced paralysis was nearly completely inhibited after addition of 100 
uM of 3,4-DAP, and this effect was sustained even after 4 h of treatment. The antagonistic 
effects of 3,4-DAP was also demonstrated in vivo, provided its concentration in the plasma 
is maintained at ~30 M during the course of intoxication (Adler et al., 2000). However, 3,4-
DAP is generally toxic, thus, its high drug concentration requirement prohibits routine 
therapeutic use (Millard, 2006).  
Mastoparan, a phospholipase activator, was evaluated for its ability to attenuate BoNT 
intoxication. Addition of mastoparan and 80 mM K+ completely prevented BoNT inhibition 
of radiolabeled acetylcholine in PC12 cells, but this effect was blocked by either EGTA or the 
N-type calcium channel blocker ω-conotoxin (Ray et al., 1999). These findings imply that the 
effects of mastoparan are dependent on Ca2+ influx via the neuronal type voltage-sensitive 
Ca2+ channels. 
4.8 Drug delivery vehicle research 
One significant challenge in the development of BoNT small-molecule therapeutics is the 
delivery of the compounds to the cytosol of peripheral cholinergic nerve cells (PCNC), 
which are the sites of BoNT action. In combination with the discovery and development of 
BoNT small-molecule inhibitors, cell-specific intracellular targeting is critical to increase the 
therapeutic index and minimize potential systemic toxicity associated with the drug 
treatment. Several studies have examined the potential of using specific recombinant BoNT 
domains or a neutralized full-length BoNT holoprotein as drug delivery system. 
Goodnough et al. observed that BoNT/A and unlabeled rHC were able to compete for 
binding, implicating specific neuronal targeting (Goodnough et al., 2002). The efficiency of 
neuron-specific cargo delivery into the cytosol was evaluated by coupling labeled dextran to 
a recombinant BoNT/A HC using a 3-(2-pyridylthio)-propionyl hydrazide linker (Zhang et 
al., 2009). A florescent tracking dye was conjugated to the dextran moiety and incubated in 
mouse cultured mouse spinal cord neurons. The binding of the fluorescent tag and its 
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internalization into the endosomes were observed, but minimal levels were detected in the 
cytosol. The movement of a small, membrane-permeable dye from the endosome into the 
cytosol is hypothesized to be due to passive diffusion instead of an active translocation 
event. Ho et al (2010) reported on a recombinant BoNT/A HC with an amino terminal GFP 
fusion that was internalized into mouse neurons; however, the GFP cargo was observed to 
be almost exclusively limited to endocytotic vesicles, with little detectable translocation into 
the cytosol. 
Although the of BoNT heavy chain comprises the domains necessary for binding and 
internalization into endosomes, recent studies suggest that all or part of the LC is essential 
to translocate a ligated cargo into the cytosol. 
Recombinant BoNT/D fusion proteins bearing amino terminal GFP, luciferase, 
dihydrofolate reductase or BoNT/A LC protein were found to promote translocation of 
cargo proteins into the cytosol in an enzymatically active form (Bade et al., 2004). A 
recombinant neutralized BoNT/A bearing an E224A E262A double mutation, labeled with 
Alexa-488, has been shown to specifically bind and internalize into human SH-SY5Y 
neuroblastoma cells (Sing et al., 2010). Additionally, this protein was found to marginally 
bind to the surface of human rhabdomyosarcoma cells with a toxicity limit of 1 µg in mice. 
No additional information is available regarding the drug conjugation study on this protein. 
Moreover, recombinant versions of full-length BoNT/A holotoxin devoid of catalytic 
activity were recently developed (Pier et al., 2008; Webb et al., 2009; Yang et al., 2008) which 
could be potentially used to deliver conjugated therapeutic cargoes. 
5. Emergency preparedness and public response 
The 2007 anthrax attacks in the United States illustrated the need to develop a 
comprehensive preparedness plan for identifying and managing healthcare resources in the 
event of a biological attack. Anthrax, plague, botulinum toxins, smallpox, tularemia, and 
viral hemorrhagic fever viruses have been identified as having a significant potential for use 
in a bioterrorism attack because they can be easily disseminated or transmitted, have high 
morbidity or mortality rates and would cause widespread social disruption (Rotz et al., 
2002). A bioterrorism attack involving dissemination of BoNT by existing food or water 
distribution networks is theoretically possible but this route is associated with significant 
logistical difficulties (Franz, et al., 1997; Zilinskas, 1999) and most experts believe that an 
aerosol dispersion poses the greatest threat (Arnon, 2002). Because botulism is a relatively 
rare disease, clinicians and the healthcare infrastructure in general have limited experience 
in diagnosis of any form of the disease. A 2005 study reported that of 631 physicians 
participating in a mock bioterrosim event, slightly less than half provided an accurate 
diagnosis and plan of management for botulism (Cosgrove, 2005). In the event of a 
biological attack with BoNT, a rapid and accurate diagnosis of the agent by physicians and 
clinical laboratories would be crucial to an equally rapid response and mobilization of 
equipment and biological agents for management. Health care providers who suspect 
botulism should immediately call their state health department's emergency 24-hour 
emergency telephone number. The state health department will contact the CDC to report 
suspected botulism cases, arrange for a clinical consultation by telephone and, if indicated, 
request release of botulinum antitoxin. State health departments should call the CDC 24-
hour telephone number at 770-488-7100. The call will be taken by the CDC Emergency 
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Operations Center, which will page the Foodborne and Diarrheal Diseases Branch medical 
officer on call. The CDC established the Laboratory Response Network (LRN) in 1999; a 
national network of about 150 federal, state, local and military labs that can respond to 
biological and chemical terrorism, and other public health emergencies (CDC-EPR). The 
LRN hierarchy also includes reference labs that can perform tests to detect and confirm the 
presence of a threat agent to ensure a rapid local response in the event of a bioterrorism 
incident without having to rely on confirmation from CDC labs. Sentinel labs are comprised 
of thousands of hospital-based labs that have direct contact with patients. These labs might 
well be the first facility to spot a suspicious specimen and refer it to the appropriate 
reference lab (Sentinel, ASM).  
The ability of the government and healthcare infrastructure to respond to a bioterroism 
attack using BoNT in a densely populated urban environment would largely dictated be by 
the ventilator and antitoxin supplies and how quickly they could be mobilized to the 
outbreak area. Approximately 120,000 of the 200,000 doses of the HBAT contracted by the 
Biomedical Advanced Research and Development Authority (BARDA) have been delivered 
for use in the US national strategic stockpile and the remaining 80,000 doses are scheduled 
for delivery by 2014. A 2010 study estimated that there are approximately 63,066 full-
featured mechanical ventilators in the US, 46.4% of which were capable of ventilating 
pediatric and neonatal patients (Rubinson et al, 2010). Additionally, there was an estimated 
82,775 additional positive pressure ventilators (PPV) that could be brought on-line in 
response to an acute respiratory failure (ARF) surge event. This study may represent a 
conservative estimate as it only accounted for survey responders and it did not consider the 
various units rented by hospitals, those facilities who failed to respond to the survey or 
those at nursing facilities or schools.  
6. Conclusion  
BoNT has been investigated as a BW by a number of different state-sponsored initiatives 
and terrorist organizations and is considered a biological threat to both our military and the 
public. Effective medical countermeasures against BoNT intoxication are limited. Currently, 
the only available treatment other than supportive care is a new investigational botulinum 
heptavalent equine-based antitoxin. However, antitoxin cannot intervene in the 
pathogenesis of the disease once the toxin enters the nerve cell, and cannot support all those 
infected in the event of a biological terrorist attack. Hence, there is a critical need for 
postintoxication therapy that can be administered rapidly and effectively to a large infected 
population. Because small molecules provide an opportunity to treat botulism both before 
and after cellular intoxication has occurred, considerable research efforts have been devoted 
to the development of these types of inhibitors. A number of strong contributions to the 
field have been made, yet no small molecule inhibitor was identified that possesses the 
appropriate characteristics (safety, efficacy, solubility) required to be a pharmaceutical 
intervention.  
Research studies addressing these obstacles are underway. Continuing efforts will be 
facilitated particularly by the availability of structural information and by knowledge of the 
mechanism of the BoNT LC-mediated proteolysis of SNARE proteins. Additionally, 
potential novel strategies to therapeutic development, e.g., host-directed therapeutics, and 
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targeting pathways involved in the cellular response to BoNT intoxication, are being 
explored. An understanding of these mechanisms may provide insight into the design and 
development of innovative and effective therapeutic strategies to counteract BoNT 
intoxications.  
7. References  
Adekar S.P., Jones, R.M. & Elias, M.D., et al. (2008). Hybridoma populations enriched for 
affinity-matured human IgGs yield high-affinity antibodies specific for 
botulinum neurotoxins. J Immunol Methods, Vol.333, No.1-2, pp. 156–166, ISSN 
0022-1759  
Adler, M., Deshpande, S.S. & Sheridan, R.E., (1994). Evaluation of captopril and other 
potentially therapeutic compounds in antagonizing botulinum toxin-induced muscle 
paralysis, In: Therapy with Botulinum Toxin; Jankovic, J., & Hallett, M. (Eds). pp. 63–
70, Marcel Dekker Inc., ISBN 0824788249, New York, NY, USA 
Adler, M., Scovill, J. & Parker, G., et al. (1995). Antagonism of botulinum toxin-induced 
muscle weakness by 3,4-diaminopyridine in rat phrenic nerve-hemidiaphragm 
preparations. Toxicon, Vol.33, No.4, pp. 527-537, ISSN 0041-0101 
Adler, M., Capacio, B. & Deshpande, S.S. (2000) Antagonism of botulinum toxin A-mediated 
muscle paralysis by 3, 4-diaminopyridine delivered via osmotic minipumps. 
Toxicon, Vol.38, No.10, pp. 1381-1388, ISSN 0041-0101 
Alberts, B. (2005). Modeling attacks on the food supply. PNAS, Vol.102, No.8, pp. 9737-9738, 
ISSN 0027-8424 
Alibek, K. & Handleman, S. (1999). Biohazard. Dell Publishing, ISBN, 0385334966, New York, 
New NY.  
Arezzo, J.C., Litwak, M.S. & Caputao, F.A., et al. (2000). Spread of paralytic activity of 
Neurobloc™ (botulinum toxin type B) and Botox® (botulinum toxin type A) in 
juvenile monkeys: an electrophysiological model. Eur J Neurol, Vol.8, No.S4, pp. 26 
ISSN 1351-5101 
Arnon, S. (1998) Infant botulism, In: Textbook of pediatric infectious diseases, Feigen, R. And 
Cherry, J. (Ed), 4th ed. W. B. Saunders, pp. 1570-1577, ISBN 0721664482 
Philadelphia, PA, USA. 
Arnon, S. (1999) Botulism as an intestinal toxaemia, In: Infections of the gastrointestinal tract, 
M.J. Baser, Guerrant, R.L. & P.D. Smith, et al. (Ed.), pp. 257-271, Raven Press, ISBN: 
0781702267, New York, NY, USA. 
Arnon, S.S., Schechter, R. & Inglesby, T., et al. (2001). Botulinum toxin as a biological 
weapon. Medical and public health management. JAMA, Vol.285, No.1, pp. 1059-
1070, ISSN 0098-7484 
Arnon SS. (2004). Infant Botulism. In: Textbook of Pediatric Infectious Diseases, Feigin, R.D., 
Cherry, J., & Demmler, G.J. (Eds) pp. 1758–1766, Saunders, ISBN 0721693296. 
Philadelphia, PA, USA 
Bade, S., Rummel, A. & Reisinger, C., et al. (2004). Botulinum neurotoxin type D enables 
cytosolic delivery of enzymatically active cargo proteins to neurons via unfolded 
translocation intermediates. J Neurochem, Vol.91, No.6, pp. 1461-1472, ISSN 0022-
3042 
www.intechopen.com
 Bioterrorism 
 
124 
Bakheit, A.M., Ward, C.D. & McClellan D.L. (1997) Generalised botulism-like syndrome 
after intramuscular injections of botulinum toxin type A: a report of two cases. J 
Neurology, Neurosurgery and Psychiatry, Vol.62, No.2, pp. 198, ISN 0022-3050 
Baird-Parker, A.C. & Freame, B. (1967). Combined effect of water activity, pH and 
temperature on the growth of Clostridium botulinum from spore and vegetative cell 
inocula. J Appl Bact, Vol.30, No.2, pp. 420-429, ISSN 0021-8847  
Barash, J.R., Tang, T.W.H., & Arnon S.S. (2005). First case of infant botulism caused by 
Clostridium baratii type F in California. J Clin Microbiol, Vol.43, No.8, pp. 4280–4282, 
ISSN 0095-1137 
BB-IND 61 Protocol CDC IBR#392, version 8.0. IND protocol: Use of penatavalent (ABCDE) 
botulinum toxin aluminum phosphate adsorbed (PBT) for workers at risk of 
occupational exposure to botulinum neurotoxins. Spnsored by: Centers for Disease 
Control and Prevention, Atlanta, GA. October 6, 2009. 
Bleck, T.P. (2009). Botulism as a potential agent of bioterrorism, In: Bioterrorism and Infectious 
Agents: A New Dilemma for the 21st Century, Fong, I.W. & Alibek, K. (Eds), pp.193-
202, Springer, ISBN 1441912657, Ney York, NY, USA 
Blix, H. (2004) Disarming Iraq. (1st ed.), Pantheon, ISBN 0375423028, New York, NY, USA. 
Benson, S.B., Passaro, D. & McGee, J., et al. (2000) Wound botulism in California, 1951-1998: 
Recent epidemic in heroin injectors. Clin Infec Dis, Vol.31, No.4, pp.1018-1024, ISN 
1058-4838 
Boles, J., West, M. & Montgomery, V.A., et al. (2006). Recombinant C fragment from 
botulinum neurotoxin B serotype (rBoNTB(Hc)) immune responses and protection 
in the rhesus monkey. Toxicon, Vol.47, No.9 pp.877-884, ISSN 0041-0101 
Boldt, G.E., Eubanks L.M. & Janda K.D. (2006). Identification of a botulinum neurotoxin A 
protease inhibitor displaying efficacy in a cellular model. Chem Commun 
(Cambridge) Vol.29, pp.3063-3065, ISSN 1359-7345 
Bozheyeva, G., Kunakbayev, Y. & Yeleukenov, D. (1999). Former soviet biological weapons 
facilities in Kazakhstan: past, present and future. Occasional paper No.1. Monterey, 
CA. Center for Nonproliferation Studies, Monterey Institute for International 
Studies, pp. 1-20  
Burnett, J.C., Schmidt, J. & Stafford, R.G., et al. (2003). Novel small-molecule inhibitors of 
botulinum neurotoxin A metalloprotease activity. Biochem Biophys Res Commun, 
Vol.310, No.1, pp. 84-93, ISSN 0006-291X 
Burnett, J.C., Wang. C., & Nuss, J.E., et al. (2009). Pharmacophore-guided lead optimization: 
the rational design of a non-zinc coordinating, submicromolar inhibitor of the 
botulinum neurotoxin serotype A metalloprotease. Bioorg Med Chem Lett, Vol.19, 
No.19, pp. 5811-5813, ISSN 0960-894X 
Burnett, J.C., Li, B. & Pai, R., et al. (2010). Analysis of botulinum neurotoxin serotype A 
metalloprotease inhibitors: analogs of a chemotype for therapeutic development in 
the context of a three-zone pharmacophore. Open Access Bioinformatics 2: 11-18. 
DOI 10.2147/OAB.S7251 
Burrows, W.D., Valcik, J.A. & Seitzinger, A. (1997). Natural and terrorst threats to drinking 
water supplies. In, Proceedsing of the 23rd environmental symposium, 7-10 April 
1997, New Orleans, LA, American Defense Preparedness Association  
www.intechopen.com
 Botulinum Neurotoxins 
 
125 
Carrus, S. (2001) Bioterroism and biocrimes. The illicit use of biological agents since 1900. 
Center for counterproliferation research, National Defense University, pp.90, ISBN 
1410100235, Washington, D.C., USA 
CDC. (1998). Botulism in the United States, 1899-1996. Handbook for epidemiologists, 
clinicians, and laboratory workers. Atlanta, GA: Centers for Disease Control and 
Prevention. Available at 
 http://www.cdc.gov/ncidod/dbmd/diseaseinfo/files/botulism.PDF 
CDC. Emergency preparedness and response (EPR). Facts about the laboratory response 
network. Accessed 08/01/2011, http://www.bt.cdc.gov/lrn/factsheet.asp 
CDC. (2010). Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed 
botulinum antitoxin AB and investigational botulinum antitoxin E. MMWR 59: 229. 
CDC. National Botulism Surveillance (NBS), accessed 08-23-2011, available from 
http://www.cdc.gov/nationalsurveillance/botulism_surveillance.html 
CDC (2006). Botulism associated with commercial carrot juice – Georgia and Florida, 
September 2006. MMWR weekly, October 13, 2006/55(40), pp. 1098-1099. 
CDC. (2007). Botulism Associated with Commercial Carrot Juice --- Georgia and Florida, 
September 2006, 08/24/2011, Available from: 
 http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5540a5.htm 
CDC. (2008). Public Health Preparedness: Mobilizing State by State 
 http://www.bt.cdc.gov/publications/feb08phprep/ 
Capková, K., Yoneda, Y. & Dickerson, T., et al. (2007). Synthesis and structure-activity 
relationships of second-generation hydroxamate botulinum neurotoxin A protease 
inhibitors. Bioorg Med Chem Lett, Vol.17, No.23, pp. 6463-6466, ISSN 0960-894X 
Capková, K., Hixon, M.S. & Pellett, S. et al. (2009). Benzylidene cyclopentenediones: First 
irreversible inhibitors against botulinum neurotoxin A’s zinc endopeptidase. Bioorg 
Med Chem Lett, Vol.20, No.1, pp. 206-208, ISSN 0960-894X 
Chang, G.Y., & Ganguly, G. (2003). Early antitoxin treatment in wound botulism results in 
better outcome. Eur Neurol, Vol.49, No.3, pp. 151-153, ISSN 0014-3022 
Chan-tack, K.M., & Bartlett J. (2010). Botulism. 
 http://emedicine.medscape.com/article/213311-overview 
Chia, J., Clark, J. & Ryan, C. (1986). Botulism in an adult associated with food-borne 
intestinal infection with Clostridium botulinum. NEJM, Vol.6, No.4, pp. 239-241, ISSN 
0028-4793 
Chen, R., Karp, B.I. & Hallett, M. (1998). Botulinum toxin type F for treatment of dystonia: 
Long-term experience. Neurology, Vol.51, No.5, pp. 1494-1496, ISSN 0028-3878 
Chertow, S., Tan, E.T. & Maslanka, S.E. et al. (2006). Botulism in 4 adults following cosmetic 
injections with an unlicensed, highly concentrated botulinum preparation. JAMA, 
Vol.296, No.20, pp.2476-2479, ISSN 0098-7484 
Cochrane, R.C. (1947). Biological warfare research in the United States, In: History of 
chemical warfare service in world war II (01 July 1940-15 August 1945). Vol.2, 
historical sections, plans, training and intelligence division, office of the chief 
chemical corps, US department of the army, 1947. Unclassified. Archived at the US 
Army Medical Research Institute for Infectious Diseases, Fort Detrick, MD.  
Collins, M.D. & East A.K. (1998). Phylogeny and taxonomy of the food-borne pathogen 
Clostridium botulinum and its neurotoxins. J App Micro, Vol.84, No.1, pp. 5-17, ISSN 
1364-5072 
www.intechopen.com
 Bioterrorism 
 
126 
Cornblath, D.R., Sladky, J.T. & Sumner, A.J. (1998). Clinical electrophysiology of infantile 
botulism. Muscle Nerve, Vol.6, No.6, pp. 448-452, ISSN 0148-639X 
Cosgrove, S.E., Perl, T.M. & Song, X., et al. (2005) Ability of physicians to diagnose and 
manage illness due to category A bioagents. Arch Int Med, Vol.165, No.17, pp. 2002-
2006, ISSN 0003-9926 
CSC Press Release. (2011). CSCs DynPort Vaccine Company Completes Vaccinations and 
Study Visits in Phase 2 Botulinum Vaccine Clinical Trial, Febraury 11, 2011, 
http://www.csc.com/dvc/press_releases/60409-
cscs_dynport_vaccine_company_completes_vaccinations_and_study_visits_in_pha
se_2_botulinum_vaccine_clinical_trial, accessed 08/01/2011 
Davis, J.B., Mattman, L.H. & Wiley, M. (1951). Clostridium botulinum in fatal wound 
infection. JAMA, Vol.146, No.7, pp. 646-648, ISSN 0098-7484 
DasGupta, B. (1989). The structure of botulinum neurotoxins, In: Botulinum Neurotoxin and 
Tetanus Toxin, pp. 53-67, Academic Press, Inc., ISBN 0306444127, New York, NY, 
USA 
Dembek, Z.F., Smith, L.A. & Rusnak, J.M. (2007). Botulinum toxin: Cause, effects, diagnosis, 
clinical and laboratory identification, and treatment modalities. Dis Med Pub Health 
Prep, Vol.1, No.2, pp. 122-134, ISSN 1935-7893 
Deshpande, S.S., Sheridan, R.E. & Adler, M. (1995). A study of zinc-dependent 
metalloendopeptidase inhibitors as pharmacological antagonists in botulinum 
neurotoxin poisoning. Toxicon, Vol.33, No.4, pp. 551-557, ISSN 0041-0101 
Deshpande, S.S., Sheridan, R.E. & Adler, M. (1997). Efficacy of certain quinolines as 
pharmacological antagonists in botulinum neurotoxin poisoning. Toxicon, Vol.35, 
No.3, pp. 433-435, ISSN 0041-0101 
Dessain, S.K., Adekar, S.P. & Stevens, J.B., et al. (2004). High efficiency creation of human 
monoclonal antibody-producing hybridomas. J Immunol Methods, Vol.291, No.1-2, 
pp. 109–122, ISSN 0022-1759 
Dong, M., Yeh, F. & Tepp, W. H., et al. (2006). SV2 Is the Protein Receptor for Botulinum 
Neurotoxin A. Science, Vol.312, No.5773 , pp. 592-596, ISSN 0036-8075 
Dunbar, E.M. (1990). Botulism, J Infect, Vol.20, No.1, pp. 1-3, ISSN 0163-4453 
Eleopra, R., Tugnoli, V. & Rosetto, O., et al. (1997). Botulinum neurotoxin serotype C: a 
novel effective botulinum therapy in humans. Neurosci Letters, Vol.224, No.2, pp.91-
94, ISSN 0304-3940 
Eleopra, R., Tugnoli, V. & Rosetto, O., et al. (1998a). Different time courses of recovery after 
poisoning with botulinum neurotoxin serotypes A and E in humans. Neurosci 
Letters, Vol.256, No.3, ISSN 0304-3940, pp. 135-138 
Eleopra, R., Tugnoli, V. & De Grandis, D., et al. (1998b). Botulinum toxin serotype C 
treatment in subjects affected by focal dystonia and resistant to toxin serotype A. 
Neurology, Vol.50, No.S4, pp. A72, ISSN 0028-3878 
Eleopra, R., Tugnoli, V, & Rocco, Q., et al. (2004). Different types of botulinum toxins in 
humans. Movement Disorders, Vol.19, No.S8, pp. S53-S59, ISSN 0885-3185 
Eubanks, L. M., Hixson, M. S., W. & Jin, W., (2007). An in vitro and in vivo disconnect 
uncovered through high-throughput identification of botulinum neurotoxin A 
antagonists. PNAS, Vol.104, No.8, pp. 2602-2607, ISSN 0027-8424 
www.intechopen.com
 Botulinum Neurotoxins 
 
127 
Feneica, L., Franciosa, G. & Pourshaban, M. (1999). Intestinal toxemia botulism in two young 
people, caused by Clostridium botulinum type E. Clin Inf Dis, Vol.29, No.6, pp. 1381-
1387, ISSN 1058-4838 
Fiock, M.A., Device, L.F. & Gearinger, et al. (1962). Studies on immunity to toxins of 
Clostridium botulinum VIII. Immunological reponses of man to purified bivalent 
botulinum toxoid. J Immun, Vol.88, No.3, ISSN 0022-1767 
Fiock, M.A., Cardell, A. & Gearinger, N.F. (1963) Studies on immunity to toxins of 
Clostridium botulinum IX. Immunological response of man to purified pentavlent 
ABCDE botulinum toxoid. J Immunology, Vol.90, No. 5, pp.697-702, ISNN 0022-1767 
Fox, C.K., Keet, C.A., & Strober, J.B. (2005). Recent advances in pediatric botulism. Pediatr 
Neurol, Vol.32, No.3, pp. 149-154, ISSN 0887-8994  
Franz, D., Parrott, C. & Takafuji, E. (1997). The U.S. Biological Warfare and Biological 
Defense Programs. In: Textbook of Military Medicine, Part I: Warfare, Weaponry, and 
Then Casualty: Medical Aspects of Chemical and Biological Warfare, Slidell, F., Takafuji, 
E. & Franz, D (Eds.) Borden Institute, Walter Reed Washington, DC, USA.  
Franz, D.R., Jahrling, P.B. & Friedlander, A.M., et al. (1997). Clinical recognition and 
management of patients exposed to biological warfare agents. JAMA, Vol.278, No.5, 
pp. 399-411, ISSN 0098-7484 
Freedman, M., Armstrong, R.M. & Killian, J.M. (1986) Botulism in a patient with jejunoileal 
bypass. Ann Neurol, Vol.20, No.5, pp. 641-643, ISSN 0364-5134, 
Gupta, A., Sumner, C.J. & Castor M, et al. (2005). Adult botulism type F in the United States, 
1981-2002. Neurology, Vol.65, No.11, pp. 1694-700, ISSN 0028-3878 
Goodnough, M.C., Oyler, G. & Fishman, P.S., et al. (2002). Development of a delivery vehicle 
for intracellular transport of botulinum neurotoxin antagonists. FEBS Lett, Vol.513, 
No.2-3, pp. 163-168, ISSN 0014-5793 
Hatheway, C.L. (1988). Botulism, In: Laboratory Diagnosis of Infectious Diseases Principles and 
Practice, Balows A., Hausler, J.W.J. & Ohashi, M. et al. (Eds), pp. 111–133, ISBN 
0387967559, Springer Scientific, New York, NY, USA 
Hatheway C.L. (1993). Clostridium botulinum and other clostridia that produce botulinum 
neurotoxin, In: Clostridium botulinum: Ecology and control in foods. Hauschild A.H.W. 
& Dodds K.L. (Eds), pp. 3-20, Marcel Dekker, Inc., ISBN 082478748X, New York, 
NY, USA. 
Hill K.K., Smith T.J. & Helma C.H., et al. (2007). Genetic diversity among botulinum 
neurotoxin-producing clostridial strains. J Bact, Vol.189, No.3, pp 818-832, ISSN 
0021-9193 
Ho, M., Chang, L.H., & Pires-Alves, M., et al. (2010). Recombinant botulinum neurotoxin A 
heavy chain-based delivery vehicles for neuronal cell targeting. Prot Eng Des Sel, 
Vol.24, No.3, pp 247-253, ISSN 1741-0126 
Holzer, E. (1962) Botulism caused by inhalation. Medizinische Klinik, Vol.31, pp.1735-740, 
ISSN 0723-5003 
Hörman, A., Nevas, M., & Lindström, M., et al. (2005). Elimination of botulinum neurotoxin 
(BoNT) type B from drinking water by small-scale (personal use) water purification 
devices and detection of BoNT in water samples. App Env Micro, Vol.71, No.4, pp. 
1941-1945, ISSN 1098-5336 
www.intechopen.com
 Bioterrorism 
 
128 
Hughes, J.M., Blumenthal, J.R. & Merson, M.D., et al. (1981) Clinical features of types A and 
B food-borne botulism. Ann Int Med, Vol.95, No.4, pp. 442-445, ISSN 0003-4819 
Jones, R.G.A, Liu, Y. & Rigsby, P. (2008). An improved method for development of toxoid 
vaccines and antitoxins. J Immun Meth, Vol.137, No.1, pp. 42-48, ISSN 0022-1759 
Keller, J.E. (2008). Characterization of new formalin-detoxified botulinum neurotoxin 
toxoids. Clin Vacc Imm, Vol.15, No.9, pp.1374-1379, ISSN 1556-6811 
Kyatkin, N., Maksymowych, & Simpson, L.A. (1997). Induction of an immune response by 
oral administration of recombinant botulinum toxin. Inf Imm, Vol.65, No.11, pp. 
4586–4591, ISSN 0019-9567 
Leitenberg, M. (1999). Aum Shinrikyo's efforts to produce biological weapons: A case study 
in the serial propagation of misinformation. Terrorism and Political Violence, Vol.11, 
No.4, pp. 152-158, ISSN 0954-6553  
Long, S.S., Gajewski, J.L. & Brown, L.W., et al. (1985). Clinical, laboratory and environmental 
features of environmental botulism in southeastern Pennsylvania. Pediatrics, Vol.75, 
No.5, pp. 935-941, ISSN 0031-4005 
Marks, J.D. (2004). Deciphering antibody properties that lead to potent botulinum 
neurotoxin neutralization. Mov Disord, Vol.19, No.S8, pp. S101–108, 0885-3185 
Mezaki, T., Kaji, R. & Kohara, N., et al. (1995). Comparison of Therapeutic Efficacies of Type 
A and F Botulinum Toxins for Blepharospasm: A double-blind, controlled study. 
Neurology, Vol.45, No.3, pp. 506-508, ISSN 0028-3878 
Merino, I., Thompson, J.D. & Millard CB, et al. (2006). Bis-imidazoles as molecular probes 
for peripheral sites of the zinc endopeptidase of botulinum neurotoxin serotype A. 
Bioorg Med Chem, Vol.14, No.10, pp. 3583-3591, ISSN 0968-0896 
Middlebrook, J.L., & Franz, D.R. (1997). Botulinum toxins. In: Textbook of Military Medicine, 
Part I: Warfare, Weaponry, and Then Casualty: Medical Aspects of Chemical and 
Biological Warfare, Sidell, F.R., Takafuji, E.T., & Franz, D.R., (Eds.) pp. 643-54. 
Borden Institute, Walter Reed Army Medical, Center Washington, DC, USA. 
Millard, C. (2006). Medical defense against toxin weapons: review and perspective. In: 
Infectious disease: biological weapons defense: infectious diseases and counterterrorism, 
Lindler, L.E., Lebeda F.J. & Korch G.W. (Eds.), pp. 255-276, Humana Press, Inc., 
ISBN 1588291847, Totowa, NJ, USA 
McLaughlin J, Funk B. 2010. New recommendations for use of heptavalent botulinum 
antitoxin (HBAT). State of AK Bull 5:1. http://www.epi.Alaska.gov 
Moe, S.T., Thompson, A.B., & Smith, G.M. et al. (2009). Botulinum neurotoxin serotype A 
inhibitors: Small-molecule mercaptoacetamide analogs. Bioorgan Med Chem, Vol.17, 
No.8, pp. 3072-3079, ISSN 0968-0896 
Moorefield, G.L., Tamariello, R., & Purcell, B. et al. (2008). An alternative approach to 
combination vaccines: intradermal administration of isolated components for 
control of anthrax, botulism, plague and staphylococcal toxic shock. J Immune Based 
Ther Vacc, Vol.6, No.5, pp. 1-11, ISSN 1476-8518 
Nowakowski, A., Wang, C. & Powers, D.B. et al. (2002). Potent neutralization of botulinum 
neurotoxin by recombinant oligoclonal antibody. PNAS, Vol.99, No.17, pp. 11346–
11350, ISSN 0027-8424 
www.intechopen.com
 Botulinum Neurotoxins 
 
129 
Notermans, S. & Havelaar, A.H. (1980). Removal and inactivation of botulinum toxins 
during production of drinking water from surface water. Antonie van Leeuwenhoek, 
Vol.46, No.5, pp. 511-514, ISSN 0003-6072 
Pang, Y.P., Davis, J., & Wang, S., et al. (2010). Small molecules showing significant 
protection of mice against botulinum neurotoxin serotype A. PLoS ONE, Vol. 5, No. 
4, pp. e10129, ISSN 1932-6203 
Park, J.G., Sill, P.C. & Makiyi, E.F. et al. (2006). Serotype-selective, small-molecule inhibitors 
of the zinc endopeptidase of botulinum neurotoxin serotype A. Bioorg Med Chem, 
Vol.14, No.2, pp. 395–408, ISSN 0968-0896 
Parker, H.S. (2002) Agricultural Bioterrorism: A federal strategy to meet the threat. McNair paper 
65, Institute for National Strategic Studies, ISSN 1071-7552, Washington D.C., USA 
Partikan, A., & Mitchell, W.G. (2007). Iatrogenic botulism in a child with spastic 
quadriparesis. J Child Neur, Vol.16, No.22, pp. 1235-1237, 0883-0738 
Pickett, J., Berg, B. & Chaplin, E. et al. (1976). Syndrome of botulism in infancy: clinical and 
electrophysiological study. NEJM, Vol.295, No.14, pp.770-772, ISSN 0028-4793 
Pier, C.L., Tepp, W.H., & Bradshaw, M., et al. (2008). Recombinant holotoxoid vaccine 
against botulism. Infect Immun, Vol.76, No.1, pp. 437-42, ISSN 0019-9567 
Ravichandran, E., Gong, Y. & Fetwah, H. et al. (2005). An initial assessment of the systemic 
pharmacokinetics of botulinum toxin. J Pharm Exp Ther, Vol.318, No.3, pp. 1343-
1351, ISSN 0022-3565 
Ray, P., Ishida, H. & Millard, C.B., et al. (1999). Phospholipase A2 and arachidonic acid-
mediated mechanism of neuroexocytosis: a possible target of botulinum neurotoxin 
A other than SNAP-25. J Appl Toxicol, Vol.19, No.S1, pp. S27-28, ISSN 0260-437X 
Razai, A., Garcia-Rodriguez, C. & Lou, J. et al. (2005). Molecular evolution of antibody 
affinity for sensitive detection of botulinum neurotoxin type A. J Mol Biol, Vol.351, 
No.1, pp. 158–169, ISSN 0022-2836 
Reames, H.R., Kadull, P.J. & Housewright, R.D. (1946). Studies on botulinum toxoids types 
A and B III. Immunization of man. J of Immun, Vol.55, No.4, pp. 309-324, ISSN 0022-
1767 
Rotz, L.D., Khan, A.S. & Lillibridge, S.R., et al. (2002) Public health assessment of potential 
biological terrorism agents. Emerg Inf Dis, Vol.8, No.2, pp. 225-230, ISSN 1080-6040 
Roxas-Duncan, V., Enyedy, I. & Montgomery, V.A., et al (2009). Identification and 
biochemical characterization of small-molecule inhibitors of Clostridium botulinum 
neurotoxin serotype A. Antimicrob Agents Chem, Vol.53, No.8, pp. 3478-3486, ISSN 
0066-4804 
Rubinson, L., Vaughn, F. & Nelson, S. (2010). Mechanical ventilators in US acute care 
hospitals. Dis Med Pub Health Prep, Vol.4, No.3, pp. 199-206. ISSN 1935-7893 
Rummel, A., Eichner, T. & Weil, T. et al. (2007). Identification of the protein receptor binding 
site of botulinum neurotoxins B and G proves the double-receptor concept. PNAS, 
Vol.104, No.1, pp 359-364, ISSN 0027-8424  
Rusnak, J.M. & Smith, L.A. (2009). Botulinum neurotoxin vaccines. Past history and recent 
developments. Human vaccines, Vol.5, No.12, pp. 794-805, ISSN 1554-8600 
Ryan, C.A., Nickels, M.K. & Hargrett, N.T. et al. (1987). Massive outbreak of antimicrobial 
resistant salmonellosis traced to pasteurized milk. JAMA, Vol.285, No.2, pp.3269-
3274, ISSN 0098-7484 
www.intechopen.com
 Bioterrorism 
 
130 
Sheridan R.E. (1996). Protonophore antagonism of botulinum toxin in mouse muscle. 
Toxicon, Vol.34, No.8, pp. 849-855, ISSN 0041-0101 
Scott, A.B., & Suzuki, D. (1988). Systemic toxicity of botulinum toxin by intramuscular 
injection in the monkey. Mov Dis, Vol.3, No.4, pp.333–335, ISSN 0885-3185 
Sentinel laboratory guidelines for suspected agents of bioterrorism. Botulinum toxin. ASM, 
accessed 08/01/2011, http://www.asm.org/index.php/policy/sentinel-level-
clinical-microbiology-laboratory-guidelines.html 
Settler, P.E. (2001). Pharmacology of botulinum type B. Eur J Neurol, Vol.8, No.S4, pp. 9-12, 
ISSN 1351-5101  
Shapiro, R.L., Hatheway, C. & Becher, J. et al. (1997). Botulism surveillance and emergency 
response. A public health strategy for a global challenge. JAMA, Vol.278, No.5 pp. 
433-435, ISSN 0098-7484 
Shapiro, R.L., Hatheway, C. & Swerdlow, M.D. (1998). Botulism in the United States: A 
clinical and epidemiological review. Ann Int Med, Vol.129, No.3, pp. 221-228, ISSN 
0003-4819 
Silhar, P., Capkova, K. & Salzameda, N.T. (2010). Botulinum neurotoxin A protease: 
Discovery of natural product exosite inhibitors. J Am Chem Soc, Vol.132, No.9, pp. 
2868-2869, ISSN 0002-7863 
Sing, B.R., Thirunanvukkarasu, N., & Ghosal, K., et al. (2010). Clostridial neurotoxins as a 
drug delivery vehicle targeting nervous system Biochimie, Vol.92, No.9, pp. 1252-
1259, ISSN 0300-9084 
Simpson L.L. (1982). The interaction between aminoquinoloines and presynaptically acting 
neurotoxins. J Pharmacol Exp Ther, Vol.222, No.1, pp. 43-48, ISSN 0022-3565 
Simpson L.L. 1983. Ammonium chloride and methylamine hydrochloride antagonize 
clostridial neurotoxins. J Pharmacol Exp Ther, Vol.225, No.3, pp. 546-552, ISSN 0022-
3565 
Simpson L.L. (2004). Identification of the major steps in botulinum toxin action. Ann Rev 
Pharmacol Toxicol, Vol.44, pp. 167-193, ISSN 0362-1642 
Sloop, R.R., Cole, B.A. & Esculin, R.O. (1997). Human responses to botulism injection: type B 
compared to type A. Neurology, Vol.49, No.1, ISSN 0028-3878, pp. 189-194 
Smith, L.A. (2009). Botulism and vaccines for its prevention. Vaccine, Vol.27, No.S4, pp. D33-
D39, ISSN 0264-410X 
Smith L.D.S. & Sugiyama, H. (1988). Botulism: The Organism, its Toxins, the Disease, (2nd ed.), 
Charles C. Thomas, ISBN 0398054460, Springfield, IL, USA  
Smith, T.J., Lou, J. & Geren, I.N. et al. (2005). Sequence variation within botulinum 
neurotoxin serotypes impacts antibody binding and neutralization. Infec and Imm, 
Vol.73, No.9, ISSN 0019-9567, pp. 5450-5457 
Smith, T.J., Hill, K.K. & Foley, B.T. et al. (2007). Analysis of the neurotoxin complex genes in 
Clostridium botulinum A1-A4 and B1 strains: BoNT/A3, /Ba4 and /B1 clusters are 
located within plasmids. PLosS One, Vol.2, No.12, pp.1-10, ISSN 1544-9173 
Stringer, S.C., Webb, M.D. & George, S.M. et al. (2005). Heterogeneityof times required for 
germination and outgrowth from single spores of nonproteolytic Clostridium 
botulinum. App Env Micro, Vol.71, No.9, ISSN 0099-2240, pp.4998-5003 
www.intechopen.com
 Botulinum Neurotoxins 
 
131 
Sonnabend, O., Heinzle, R. & Sigrist, T., et al. (1981). Isolation of Clostridium botulinum type 
G and identification of type G botulinal toxin in humans: report of five sudden 
unexpected deaths. J. Infect. Dis., Vol.143, No.1, ISSN 0022-1899, pp. 22–27 
Sugishima, M. (2003). Aum Shinrikyo and the Japanese law on biotrerrorism. Prehospital and 
disaster medicine, Vol.18, No.3, pp.179-183, ISSN 1049-023X 
Tacket, C.O., Shandera, W.X., & Mann, J.M., (1984). Equine antitoxin use and other factors 
that predict outcome in type A foodborne botulism. Am J Med, Vol. 76, No. 5, pp. 
794-798, ISSN 0002-9343. 
Tang J.J., Park, G., & Millard, C.B. et al. (2007). Computer-aided lead optimization: 
improved small-molecule inhibitor of the zinc endopeptidase of botulinum 
neurotoxin serotype A. PLoS ONE, Vol.2, No.8, pp. 2:e761, ISSN 1932-6203 
Terranova, W., Palumbo, J.N. & Breman, J. G. (1979). Ocular findings in botulism type B. 
JAMA, Vol.241, No.5, pp. 475-477, ISSN 0098-7484 
Tremblay, J.M., Kuo, C.L. & Abeijon, C. et al. (2010). Camelid single domain antibodies 
(VHHs) as neuronal cell intrabody binding agents and inhibitors of Clostridium 
botulinum neurotoxin (BoNT) proteases. Toxicon, Vol.56, No.6, pp. 990-998, ISSN 
0041-0101 
United Nations Security Council. (1995). Tenth report of the executive chairman of the 
special commissions established by the secretary-general pursuant to paragraph 
9(b)(I) of security council resolution 687 (1991) and paragraph 3 of resolution 699 
(1991) on the activities of the special commission. New York, pp.S/1995/1038. 
Varma, J.K., Katsitadze, G., & Moiscrafishvili, M. et al. (2004). Signs and symptoms 
predictive of death in patients with foodborne botulism-Republic of Georgia, 1980-
2002. Clin Infect Dis, Vol.39, No.33, pp.357-362, ISSN 1058-4838 
Wannemacher, R.W., Dinterman, R.E., & Thompson, W.L. et al. (1993) Treatment for 
removal of biotoxins from drinking water. Technical report 9120. U.S. Army 
Biomedical Research and Development Laboratory, Fort Detrick, Frederick, Md. 
Wein, L.M. & Liu, Y. (2005) Analyzing a bioterror attack on the food supply: The case of 
botulinum toxin in milk. PNAS, Vol.102, No.28, pp. 9984-9899, ISSN, 0027-8424 
Webb, R.P., Smith, T.J. & Wright, P. et al. (2009). Production of catalytically inactive 
BoNT/A1 holoprotein and comparison with BoNT/A1 subunit vaccines against 
toxin subtypes A1, A2, and A3. Vaccine, Vol.27, No.33, pp. 4490-4497, ISSN 0264-
410X 
Woodruff, B.A., Griffin, P.M. & McCroskey L.M. (1992). Clinical and laboratory comparison 
of botulism from toxin types A, B, and E in the United States, 1975-1988. J Infect Dis, 
Vol.166, No.6, pp. 1281-12866, ISSN 0022-1899 
Williams, P. & Wallace, D. (1989). Unit 731: Japan’s Secret Biological Warfare in World War II. 
The Free Press, ISBN 0029353017, New York, NY, USA. 
Yang, Y., Lindo, P. & Riding, S. et al. (2008). Expression, purification and comparative 
characterization of enzymatically deactivated recombinant botulinum neurotoxin 
type A. Botulinum Vol.1, No.2, pp. 219-241, ISSN 1754-7318 
Yuan, J., Inami, G., & Mohle-Boetani, J. (2011) Recurrent wound botulism among injection 
drug users in California. Clin Infec Dis, Vol.52, No.7, pp. 862-866, ISSN 1058-4838  
Zhang, P., Ray, R., & Sing, B.R., et al. (2009) An efficient drug delivery vehicle for botulism 
countermeasure. BMC Pharm, Vol.9, No.12, pp. 1-9, ISSN 1471-2210 
www.intechopen.com
 Bioterrorism 
 
132 
Zilinkas, R.A. (1997). Iraq’s biological weapons: the past as future? JAMA, Vol.278, No.5, pp. 
418-424, ISSN 0098-7484 
www.intechopen.com
Bioterrorism
Edited by Dr. Stephen Morse
ISBN 978-953-51-0205-2
Hard cover, 192 pages
Publisher InTech
Published online 28, March, 2012
Published in print edition March, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
This book consists of nine chapters, written by international authorities, discussing various aspects of
bioterrorism preparedness and response. Five of the chapters are agent-specific and highlight the
pathogenesis, prevention and treatment, and the potential of specific organisms (Rickettsia and Yersinia
pestis) or toxins (ricin, botulinum neurotoxins, and staphylococcal enterotoxins) to be used for nefarious
purposes. Four chapters discuss different aspects of detecting and responding to a bioterrorism attack. These
include methods for spatio-temporal disease surveillance, international laboratory response strategies,
detection of botulinum neurotoxins in food and other matrices, and the use of physical methods (ie Raman
spectroscopy) to detect spores.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Robert P. Webb, Virginia I. Roxas-Duncan and Leonard A. Smith (2012). Botulinum Neurotoxins, Bioterrorism,
Dr. Stephen Morse (Ed.), ISBN: 978-953-51-0205-2, InTech, Available from:
http://www.intechopen.com/books/bioterrorism/botulinum-neurotoxins1
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
